NasdaqGS:DYNBiotechs
What Dyne Therapeutics (DYN)'s DELIVER Data and $350 Million Raise Mean For Shareholders
Earlier in December 2025, Dyne Therapeutics reported positive topline results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial, showing z-rostudirsen increased muscle content-adjusted dystrophin expression to 5.46% of normal in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Alongside these data, Dyne completed a US$350.00 million follow-on common stock offering, reinforcing its financial capacity to advance z-rostudirsen and related...